Instapmoment schreef op 19 oktober 2023 16:52:
[...]
Dat zou nog wel eens kunnen meevallen. Ik zie op de website van IMMP een nieuw analyst report van Wilson: tot mijn verbazing staan daarin details van de ESMO abstract.
"Overall survival (OS), the primary endpoint for the upcoming Phase III trial, remained at 25.0 months in the focus cohort, being PD-L1 =1%. This compares to ~16.7 months with pembrolizumab alone in a comparative patient population."
Geen verdere verbetering dus voor PD-L1=1%, maar nog steeds significant beter dan de huidige standard-of-care pembrolizumab. Maar dan komt het:
The high PD-L1 expressers (TPS = 50%) were the
standout with median OS of 38.8 months, almost doubling current options (~20 months for SOC including chemotherapy combos). These data, when compared to their chosen SOC comparator regimen for TACTI-004, show
marked survival superiority (mPFS, mOS), which if replicated in the upcoming Phase III program (TACTI-004)
should support the emergence of Efti as a revolutionary new IO combination therapy option for current anti-PD-1 blockbusters. We look forward to incremental data and detail to come following the ESMO presentation on Oct 21st.
www.immutep.com/files/content/investo...